VCM
PTGX icon

Versant Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Versant Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.31K Hold
27
– – ﹤0.01% 2504
2026
Q1 		$2.85K Hold
27
– – ﹤0.01% 2507
2025
Q4 		$2.36K Hold
27
– – ﹤0.01% 2421
2025
Q3 		$1.79K Sell
27
-2
-7% -$114 ﹤0.01% 2428
2025
Q2 		$1.6K Buy
+29
New +$1.39K ﹤0.01% 2419

Other funds holding PTGX

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return
CA
Cache Advisors San Francisco, California $1.18B AUM 44.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Versant Capital Management's PTGX Position: Q2 2026 in Review

Versant Capital Management held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 27 shares worth $3.31K. The position accounts for ﹤0.01% of the portfolio, ranked #2504.

Versant Capital Management first reported a position in PTGX in Q2 2025 and has held it in 5 quarters since. 25 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Versant Capital Management held 27 shares of Protagonist Therapeutics worth $3.31K as of Q2 2026.
  • Versant Capital Management left its Protagonist Therapeutics share count unchanged in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2504 holding.
  • Versant Capital Management first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 25 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.